Market commentators predict that MGAs fare better in the current soft market cycle versus their insurer peers – but does this success have an end date or is ‘the rise of MGAs’ unstoppable?
The government and independent bodies concur that AI technology should unlock a wealth of opportunity for the financial services sector – but only if market firms can satisfy skills gaps with tailored training
Is UKGI too focused on being a stickler for Consumer Duty rules, without properly considering the ethos and spirit of this outcomes centred regulation? Claims processes could be the rub here…
Zurich believes the suggested deal will create a global leader in specialty insurance, but Beazley is urging its shareholders ’to take no action’ after the latest takeover proposal was submitted to the insurer
The artificial intelligence trouble-bubble will pop, but are UKGI firms prepared for the fallout and how it could impact their businesses?
UK insurance staffers need to stop treating networking introductions like a finite commodity and adopt a more American mindset to collaboration if they want to nurture professional allies for the long term
The sector should make a bigger deal of its diversity and inclusion wins
Broker chief executive describes 2026 as ‘a year of enormous possibilities’, with falling reinsurance rates giving primary insurers scope to explore their strategic options
There was nothing particularly exciting about the regulator’s statement on the home and travel insurance markets, but what did we expect?
The big have only gotten bigger as an integration focus from UKGI brokers has hit pause on rampaging acquisitional growth, leading to static table standings for the first time in report’s history
UK general insurance has broker consolidators aplenty – but what does the next stage of their growth journeys look like? Gossip in the sector’s rumour mill has a suggestion…
Innovation cycles within organisations are currently interconnected with hard and soft market conditions – but companies should take inspiration from their own body cells to treat innovation as a natural function rather than a stimulant